Ch Dittrich Selected Research

Carboplatin (JM8)

5/2003

Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ch Dittrich Research Topics

Disease

2	Agranulocytosis (Granulocytopenia) 03/2005 - 05/2003
2	Ovarian Neoplasms (Ovarian Cancer) 03/2005 - 05/2003
1	Carcinoma (Carcinomatosis) 03/2005
1	Neoplasm Metastasis (Metastasis) 03/2005
1	Ovarian Epithelial Carcinoma 05/2003
1	Nausea 05/2003
1	Thrombocytopenia (Thrombopenia) 05/2003
1	Vomiting 05/2003
1	Neoplasms (Cancer) 10/2002
1	Breast Neoplasms (Breast Cancer) 01/2002

Drug/Important Bio-Agent (IBA)

2	PlatinumIBA 03/2005 - 05/2003
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 03/2005
1	Etoposide (VP 16)FDA LinkGeneric 03/2005
1	Carboplatin (JM8)FDA LinkGeneric 05/2003
1	Cisplatin (Platino)FDA LinkGeneric 05/2003
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2003
1	SulfonamidesIBA 10/2002
1	Antineoplastic Agents (Antineoplastics)IBA 10/2002
1	N- (3- chloro- 7- indolyl)- 1,4- benzenedisulphonamide (E7070)IBA 10/2002

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 03/2005
1	Therapeutics 01/2002